JP2019506166A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506166A5
JP2019506166A5 JP2018539962A JP2018539962A JP2019506166A5 JP 2019506166 A5 JP2019506166 A5 JP 2019506166A5 JP 2018539962 A JP2018539962 A JP 2018539962A JP 2018539962 A JP2018539962 A JP 2018539962A JP 2019506166 A5 JP2019506166 A5 JP 2019506166A5
Authority
JP
Japan
Prior art keywords
seq
nucleotides
nucleic acid
acid molecule
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018539962A
Other languages
English (en)
Japanese (ja)
Other versions
JP7217630B2 (ja
JP2019506166A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015879 external-priority patent/WO2017136358A1/en
Publication of JP2019506166A publication Critical patent/JP2019506166A/ja
Publication of JP2019506166A5 publication Critical patent/JP2019506166A5/ja
Priority to JP2022068361A priority Critical patent/JP2022089920A/ja
Application granted granted Critical
Publication of JP7217630B2 publication Critical patent/JP7217630B2/ja
Priority to JP2024102527A priority patent/JP2024114805A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018539962A 2016-02-01 2017-01-31 最適化第viii因子遺伝子 Active JP7217630B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022068361A JP2022089920A (ja) 2016-02-01 2022-04-18 最適化第viii因子遺伝子
JP2024102527A JP2024114805A (ja) 2016-02-01 2024-06-26 最適化第viii因子遺伝子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662289696P 2016-02-01 2016-02-01
US62/289,696 2016-02-01
US201662409739P 2016-10-18 2016-10-18
US62/409,739 2016-10-18
PCT/US2017/015879 WO2017136358A1 (en) 2016-02-01 2017-01-31 Optimized factor viii genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022068361A Division JP2022089920A (ja) 2016-02-01 2022-04-18 最適化第viii因子遺伝子

Publications (3)

Publication Number Publication Date
JP2019506166A JP2019506166A (ja) 2019-03-07
JP2019506166A5 true JP2019506166A5 (OSRAM) 2020-01-30
JP7217630B2 JP7217630B2 (ja) 2023-02-03

Family

ID=58044178

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018539962A Active JP7217630B2 (ja) 2016-02-01 2017-01-31 最適化第viii因子遺伝子
JP2022068361A Pending JP2022089920A (ja) 2016-02-01 2022-04-18 最適化第viii因子遺伝子
JP2024102527A Pending JP2024114805A (ja) 2016-02-01 2024-06-26 最適化第viii因子遺伝子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022068361A Pending JP2022089920A (ja) 2016-02-01 2022-04-18 最適化第viii因子遺伝子
JP2024102527A Pending JP2024114805A (ja) 2016-02-01 2024-06-26 最適化第viii因子遺伝子

Country Status (24)

Country Link
US (2) US11753461B2 (OSRAM)
EP (2) EP3411478B1 (OSRAM)
JP (3) JP7217630B2 (OSRAM)
KR (1) KR20180118659A (OSRAM)
CN (2) CN116218863A (OSRAM)
AU (2) AU2017214378B2 (OSRAM)
CA (1) CA3012695A1 (OSRAM)
CL (1) CL2018002054A1 (OSRAM)
CO (1) CO2018009120A2 (OSRAM)
DK (1) DK3411478T3 (OSRAM)
ES (1) ES2926585T3 (OSRAM)
HR (1) HRP20221089T1 (OSRAM)
HU (1) HUE059941T2 (OSRAM)
IL (2) IL320404A (OSRAM)
LT (1) LT3411478T (OSRAM)
MX (2) MX2018009375A (OSRAM)
NZ (1) NZ745831A (OSRAM)
PH (1) PH12018501628B1 (OSRAM)
PL (1) PL3411478T3 (OSRAM)
PT (1) PT3411478T (OSRAM)
RS (1) RS63548B1 (OSRAM)
SG (2) SG11201806398YA (OSRAM)
SI (1) SI3411478T1 (OSRAM)
WO (1) WO2017136358A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3889173T5 (da) 2013-02-15 2024-08-05 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
CN111247251B (zh) 2017-08-09 2025-06-27 比奥维拉迪维治疗股份有限公司 核酸分子及其用途
JP2021512126A (ja) * 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第viii因子を発現するレンチウイルスベクターの使用
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
WO2019169245A1 (en) 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
EP3833766A1 (en) * 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CN113396223A (zh) * 2018-12-06 2021-09-14 比奥维拉迪维治疗股份有限公司 表达因子ix的慢病毒载体的用途
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
CN115279896A (zh) * 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
CN111647625A (zh) * 2019-12-25 2020-09-11 深圳三智医学科技有限公司 一种提高人凝血因子ix表达水平的方法
CN111808863B (zh) * 2020-06-23 2021-05-28 康霖生物科技(杭州)有限公司 一种密码子优化的凝血因子viii基因及其构建体
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
EP4392444A1 (en) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Engineered itr sequences and methods of use
AU2022332276A1 (en) * 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
AU2022334711A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Baculovirus expression system
IL311725A (en) * 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
EP4511055A2 (en) * 2022-04-20 2025-02-26 AskBio Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
JP2025515356A (ja) * 2022-04-28 2025-05-14 ジョイント・ストック・カンパニー “バイオキャド” Fviii-bddおよび異種シグナルペプチドに基づく融合タンパク質をコードする単離された核酸
WO2025219525A1 (en) 2024-04-19 2025-10-23 Fondazione Telethon Combinations, inhibitors, viral vectors, methods, and uses for in vivo gene therapy and gene editing

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
EP0669986B1 (en) 1992-11-13 2003-04-09 Idec Pharmaceuticals Corporation Fully impaired consensus kozac sequences for mammalian expression
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
CA2264483C (en) 1996-09-06 2011-03-22 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
CN1195863C (zh) 1996-10-17 2005-04-06 牛津生物医学(英国)有限公司 逆转录病毒载体
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
CN1175111C (zh) 1997-03-14 2004-11-10 艾德药品公司 将基因整合至哺乳动物细胞特定位点的方法及所用载体
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20090148906A1 (en) 1998-09-29 2009-06-11 Shire Human Genetic Therapies, Inc. A Delaware Corporation Optimized messenger rna
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7250299B1 (en) 1999-04-29 2007-07-31 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US20020159978A1 (en) 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
US6888319B2 (en) 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
JP2005501547A (ja) 2001-09-04 2005-01-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 修飾された第ix因子
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
ATE317916T1 (de) 2001-11-13 2006-03-15 Univ Pennsylvania Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド アルブミン融合タンパク質
US6899917B2 (en) 2001-12-27 2005-05-31 3M Innovative Properties Company Powdered epoxy composition
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN101143221A (zh) 2002-03-15 2008-03-19 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
US6615782B1 (en) 2002-04-12 2003-09-09 Delphi Technologies, Inc. Two-step finger follower rocker arm
WO2003100053A1 (en) 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Fc 변이체 및 그의 제조 방법
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
US8501464B2 (en) 2003-04-24 2013-08-06 Ospedale San Raffaele S.R.L. Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1769078A1 (en) 2004-07-01 2007-04-04 VIRxSYS Corporation Vector packaging cell line
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP2940043A1 (en) 2004-07-15 2015-11-04 Xencor, Inc. Optimized fc variants
ES2436741T3 (es) 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
HUE027013T2 (en) 2005-05-27 2016-10-28 Ospedale San Raffaele Srl A gene vector containing MI-RNA
EP1908797B1 (en) 2005-07-05 2012-06-06 Kaneka Corporation Methacrylic resin composition
EP1924596A4 (en) 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
EP1945779B1 (en) 2005-10-20 2013-03-06 UniQure IP B.V. Improved aav vectors produced in insect cells
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
KR20090019770A (ko) 2006-03-13 2009-02-25 티아이알 테크놀로지 엘피 고상 조명 시스템용 적응형 제어 장치 및 전압 결정 방법
CN101511373B (zh) 2006-06-19 2015-12-09 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
TW200804416A (en) 2006-06-19 2008-01-16 Nautilus Technology Llc Modified coagulation factor IX polypeptides and use thereof for treatment
CN101506369B (zh) 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
KR20090064453A (ko) 2006-09-14 2009-06-18 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US8167585B2 (en) 2006-09-28 2012-05-01 Siemens Industry, Inc. Devices and/or systems for mounting an auxiliary blower
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008131242A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
CA2702363A1 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
WO2009075772A1 (en) 2007-12-06 2009-06-18 Wyeth Crystal structure of human factor viii and uses thereof
BRPI0910702A2 (pt) 2008-04-16 2016-07-05 Bayer Healthcare Llc polipeptídeos de fator ix modificados e usos dos mesmos
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
US10273502B2 (en) 2008-06-18 2019-04-30 Oxford Biomedica (Uk) Limited Virus purification
EP2307551B1 (en) 2008-06-18 2016-12-14 Oxford BioMedica (UK) Limited Purification of retroviral vectors
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
EP2364362B1 (en) 2008-11-12 2015-10-21 Ospedale San Raffaele S.r.l. Gene vector for inducing transgene-specific immune tolerance
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US9050269B2 (en) 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
WO2010115866A1 (en) 2009-04-06 2010-10-14 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
EA023938B1 (ru) 2009-04-30 2016-07-29 Оспедале Сан Рафаэлле С.Р.Л. Вектор гена
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US20120134977A1 (en) 2009-06-01 2012-05-31 Yeda Research And Development Co. Ltd. Prodrugs containing albumin binding probe
CA2764105A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102481331B (zh) 2009-06-08 2017-09-22 阿穆尼克斯运营公司 葡萄糖调节多肽及其制备和使用方法
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
MX2012003175A (es) 2009-09-18 2012-04-11 Micromet Ag Regimen de dosificacion para administrar un anticuerpo bi-especifico epcamxcd3.
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
ME02964B (me) 2009-12-06 2018-07-20 Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
KR101578686B1 (ko) 2010-02-23 2015-12-21 사노피 항-알파2 인테그린 항체 및 그 용도
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
AU2011274414B2 (en) 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SI2591006T1 (sl) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CA2837995A1 (en) 2011-06-03 2012-12-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
EP2729161B1 (en) 2011-07-08 2018-12-19 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
RS59670B1 (sr) 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
EA201491388A1 (ru) 2012-02-15 2015-01-30 Байоджен Айдек Ма Инк. Рекомбинантные белки фактора viii
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
CN103316356B (zh) 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN104661674A (zh) 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
RU2500816C1 (ru) 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
DK3889173T5 (da) 2013-02-15 2024-08-05 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
CN114736305B (zh) 2014-01-10 2023-05-05 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
ES3009565T3 (en) 2015-04-16 2025-03-27 Univ Emory Recombinant promoters and vectors for protein expression in liver and use thereof
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
EP3377618B1 (en) 2015-11-19 2020-11-18 Novartis AG Buffers for stabilization of lentiviral preparations
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
JP2021512090A (ja) 2018-01-30 2021-05-13 モデルナティーエックス, インコーポレイテッド 免疫細胞に薬剤を送達するための組成物及び方法
JP2021512126A (ja) 2018-02-01 2021-05-13 バイオベラティブ セラピューティクス インコーポレイテッド 第viii因子を発現するレンチウイルスベクターの使用
US20220193222A1 (en) 2018-11-30 2022-06-23 Vaccine Stabilization Institute Viral formulations containing amino acids
CN113396223A (zh) 2018-12-06 2021-09-14 比奥维拉迪维治疗股份有限公司 表达因子ix的慢病毒载体的用途
CN115279896A (zh) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 慢病毒载体配制品
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
BR112023002395A2 (pt) 2020-08-23 2023-03-21 Bioverativ Therapeutics Inc Sistema de baculovírus modificado para produção aprimorada de dna com extremidades fechadas (cedna)

Similar Documents

Publication Publication Date Title
JP2019506166A5 (OSRAM)
HRP20221089T1 (hr) Optimizirani geni faktora viii
JP2018537087A5 (OSRAM)
KR102638978B1 (ko) Rsv에 대한 백신
Li et al. Cloning, expression, isotope labeling, and purification of human antimicrobial peptide LL-37 in Escherichia coli for NMR studies
FI3889173T3 (fi) Optimoitu tekijä viii:n geeni
Marriott et al. Comparison of the S RNA segments and nucleoprotein sequences of Crimean-Congo hemorrhagic fever, Hazara, and Dugbe viruses
JP2002500043A5 (OSRAM)
JP2013502226A5 (OSRAM)
JP2014508510A5 (OSRAM)
JP2017503509A5 (OSRAM)
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
JP2019535268A5 (ja) アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
JP2002514418A5 (OSRAM)
JP2016523919A5 (OSRAM)
JP2018537089A5 (OSRAM)
JPWO2021219897A5 (OSRAM)
WO2000026244A3 (en) A novel tumor necrosis factor family member, drl, and related compositions and methods
WO2022032660A1 (zh) 新型冠状病毒rbd融合蛋白
JPWO2019152692A5 (OSRAM)
JPWO2021243122A5 (OSRAM)
JP2020518613A5 (OSRAM)
JP2007536891A5 (OSRAM)
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
ATE501256T1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung